We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

MINDRAY In-Vitro Diagnostics

  Gold Mindray offers a range of chemistry and hematology analyzers, designed to meet the needs of smaller labs as a main in... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Mindray Launches High Throughput BS-600M Chemistry Analyzer with Industry-Leading Small Footprint

By LabMedica International staff writers
Posted on 16 May 2022
Print article
Image: The new BS-600M chemistry analyzer provides a complete package to help labs grow (Photo courtesy of Mindray)
Image: The new BS-600M chemistry analyzer provides a complete package to help labs grow (Photo courtesy of Mindray)

Mindray (Shenzhen, China) has launched the new BS-600M, a powerful yet efficient chemistry analyzer designed to empower medium-volume laboratories with increased productivity, efficiency and reliability.

With a compact footprint of only 1.2 square meters and a throughput of 600 T/H (up to 800 T/H with ISE), the BS-600M chemistry analyzer has among the highest levels of throughput per square meter. It maximizes productivity for laboratories in a minimum amount of space. BS-600M allows continuous sample loading by racks and flexible STAT priority, which enables higher efficiency and prolonged walk-away time. Having high Sigma metric performance, it can help laboratories deliver high levels of testing quality, reduce QC measurements, simplify QC rules, and shorten turn-around time. These advantages enable significant reductions in troubleshooting work and consumption of QCs and reagents.

BS-600M features on-board hemolysis with whole blood for HbA1c tests. This eliminates the need for manual pretreatment, improving testing efficiency and reducing biohazardous risks and human errors. Mindray’s HbA1c assay on BS-600M can achieve excellent accuracy and precision. The enzymatic HbA1c method can also effectively prevent interferences from Hb variants and ensure no interference from other Hb derivatives. This means that reliable results can be obtained at the first measurement, without requiring further confirmations. Additionally, BS-600M requires much reduced reaction volumes for HbA1c tests, which contributes to around 30% lower cost per test. BS-600M also integrates a brand-new ISE solution, which reduces both the frequency of electrode replacement and the consumption of ISE reagents. As the result, the cost per test for ISE is reduced by around 35%. Moreover, ISE tests on BS-600M exhibit top levels of accuracy and precision in the field of ISE detection.

BS-600M also incorporates several other powerful functions, including intelligent detection, alarming and auto-rerun of abnormal reactions, fast input of QC & CAL target values via barcode scanning, a user-friendly operation interface, and breathing LEDs that indicate the status of the analyzer. All these powerful functions allow BS-600M to help medium-sized laboratories maximize their working efficiency and cost efficiency, and provide an amazing user experience for laboratory technicians. The performance advantages of BS-600M allow it to offer highly reliable results at reduced costs and to enhance clinician confidence and satisfaction.

Related Links:
Mindray 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
ESR Analyzer
miniiSED™
New
Platinum Supplier
Hormonal Test
Endocrine Array
New
3-Part Diff Hematology Analyzer
HEMIX 3-60

Print article

Channels

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.